

Figure 5A





Figure 5B



Dox




Figure 5C

5-Fluorouracil (ng/ml)

Figure 5D

Phylogix

Days after the initial dose of 5-FU

“Optimized”

5-FU
FRL ↓ ↓ ↓

During

5-FU
FRL ↓ ↓ ↓

Pre-treatment

5-FU
FRL ↓ ↓ ↓

A

B

C

Figure 6

Improved Survival of FRIL-Treated Mice




Figure 7

Phylogix

卷之三

P2-66 D5




Figure 8

Days after the initial dose of 5-FU

Phylogix

FRIL Prevents Wasting of Mice in the Two-Dose 5-FU Chemoprotection Model




Figure 9A




Figure 9B

2022-09-20 - Segregation




Figure 10

Kollet and Lapidot
Weizmann Institute

Phylogix

Cytokines Expand Cell Number and Progenitors After Culture in FRIL

Figure 11A




Figure 11A

Figure 11B

Kollet et al, Weizmann Institute
Phylogix

Figure 1A




Figure 1B




Figure 1C





Figure 1D



Phylogix

Activation Status of FRIL-Selected Cord Blood Cells

Figure 2A





Figure 2B



CD38

Phylogix

© 2002 Phylogix. All rights reserved. Phylogix is a registered trademark of Phylogix Corporation.

Response of FRIL-Selected CB Cells to Endothelial and Hematopoietic Stimuli




Figure 3A

Figure 3B

Phylogix

Receptor Tyrosine Kinase (RTK) Expression in FRIL-Selected CB Cell Populations




Figure 4

Phylogix